Design Therapeutics (DSGN) Stock: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$10.15
-0.53 (-4.96%)
▼
5d:
-1.84%
30d:
-17.75%
90d:
-23.11%
BUY
HIGH Confidence
Analysis Updated: Nov 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
TODAY
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DSGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: DSGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $10.15, which is considered oversold relative to its 30-day fair value range of $10.30 to $12.06.
Technical Outlook: Technically, DSGN is in a downtrend. The price is currently testing key support at $10.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: DSGN scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.71 (+113.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DSGN is in a downtrend. The price is currently testing key support at $10.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: DSGN scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.71 (+113.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.30 -
$12.06
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
91.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 113.9% below Wall St target ($21.71)
- BULLISH: Bottoming setup score 73/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$10.30 -
$12.06
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.27
(12.5%)
Support & Resistance Levels
Support Level
$10.09
Resistance Level
$11.50
Current Trend
Downtrend
Technical data as of
Nov 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.27
Wall Street Target
$21.71
(+113.9%)
Share & Embed Analysis
Last updated: November 03, 2026 4:05 AM ET
Data refreshes hourly during market hours. Next update: 5:05 AM
Data refreshes hourly during market hours. Next update: 5:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$259 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$107 | 61 BUY |
